Research programme: microRNA-targeted therapeutics - Rosetta Genomics

Drug Profile

Research programme: microRNA-targeted therapeutics - Rosetta Genomics

Alternative Names: miR-34a therapeutics - Rosetta/Weizmann Institute

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rosetta Genomics
  • Developer Rosetta Genomics; Weizmann Institute of Science
  • Class Antisense oligonucleotides
  • Mechanism of Action RNA inhibitors; Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
  • 06 Feb 2017 Rosetta Genomics receives patent allowance for hsa-miR-146-5p and hsa-miR-551b-3p for the treatment of Cancer in USA
  • 23 Sep 2015 Rosetta Genomics receives patent allowance for anti-hsa-miR-210 for the treatment of Prostate cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top